子宫内膜癌中PD-1和PD-L1阻断联合化疗。回复。 - Suppr

Suppr

超能文献

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply.

作者信息

Mirza Mansoor R, Powell Mathew A

机构信息

Rigshospitalet, Copenhagen, Denmark

Washington University School of Medicine, St. Louis, MO.

出版信息

N Engl J Med. 2023 Aug 31;389(9):867. doi: 10.1056/NEJMc2308037.

DOI:10.1056/NEJMc2308037

PMID:37646695

Abstract

摘要

相似文献

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply.

N Engl J Med. 2023 Aug 31;389(9):867. doi: 10.1056/NEJMc2308037.

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply.

N Engl J Med. 2023 Aug 31;389(9):867-868. doi: 10.1056/NEJMc2308037.

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.

N Engl J Med. 2023 Aug 31;389(9):866-867. doi: 10.1056/NEJMc2308037.

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.

N Engl J Med. 2023 Aug 31;389(9):866. doi: 10.1056/NEJMc2308037.

The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.

Curr Treat Options Oncol. 2018 Nov 5;19(12):70. doi: 10.1007/s11864-018-0593-2.

Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.

Oncologist. 2017 Apr;22(4):470-479. doi: 10.1634/theoncologist.2016-0419. Epub 2017 Mar 8.

Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.

Cancer. 2024 May 1;130(9):1642-1649. doi: 10.1002/cncr.35179. Epub 2024 Jan 5.

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10.

Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.

J Cancer Res Clin Oncol. 2021 Aug;147(8):2459-2469. doi: 10.1007/s00432-021-03527-4. Epub 2021 Feb 1.

Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.

Gynecol Oncol. 2018 May;149(2):381-387. doi: 10.1016/j.ygyno.2018.02.013. Epub 2018 Mar 21.

引用本文的文献

Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis.

Cost Eff Resour Alloc. 2025 Jun 12;23(1):29. doi: 10.1186/s12962-025-00625-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply.

作者信息

Mirza Mansoor R, Powell Mathew A

机构信息

Rigshospitalet, Copenhagen, Denmark

Washington University School of Medicine, St. Louis, MO.

出版信息

N Engl J Med. 2023 Aug 31;389(9):867. doi: 10.1056/NEJMc2308037.

DOI:10.1056/NEJMc2308037

PMID:37646695

Abstract

摘要

相似文献

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply.

N Engl J Med. 2023 Aug 31;389(9):867. doi: 10.1056/NEJMc2308037.

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer. Reply.

N Engl J Med. 2023 Aug 31;389(9):867-868. doi: 10.1056/NEJMc2308037.

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.

N Engl J Med. 2023 Aug 31;389(9):866-867. doi: 10.1056/NEJMc2308037.

PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer.

N Engl J Med. 2023 Aug 31;389(9):866. doi: 10.1056/NEJMc2308037.

The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.

Curr Treat Options Oncol. 2018 Nov 5;19(12):70. doi: 10.1007/s11864-018-0593-2.

Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.

Oncologist. 2017 Apr;22(4):470-479. doi: 10.1634/theoncologist.2016-0419. Epub 2017 Mar 8.

Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.

Cancer. 2024 May 1;130(9):1642-1649. doi: 10.1002/cncr.35179. Epub 2024 Jan 5.

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10.

J Cancer Res Clin Oncol. 2021 Aug;147(8):2459-2469. doi: 10.1007/s00432-021-03527-4. Epub 2021 Feb 1.

Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.

Gynecol Oncol. 2018 May;149(2):381-387. doi: 10.1016/j.ygyno.2018.02.013. Epub 2018 Mar 21.

引用本文的文献

Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis.

Cost Eff Resour Alloc. 2025 Jun 12;23(1):29. doi: 10.1186/s12962-025-00625-9.